Skip to main content

Table 2 CTC counts before and after treatment

From: Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study

CTC Timing

CTC Positivity/Determinations

CTC1

 ≥1 cells/7.5 ml (%) (range)

5/65 (7.5%) (1-6)

 0 cells /7.5 ml

60

CTC2

 ≥1 cells/7.5 ml (range)

8/62(12.9%) (1-1)

New presentation in 6

 0 cells /7.5 ml

54

 Not performed

3

CTC3

 ≥1 cells/7.5 ml (range)

11/59 (18.6%) (1-136)

New presentation in 10

 0 cells /7.5 ml

48

 Not performed

6

CTC4

 ≥1 cells/7.5 ml (range)

1/13 (7.6%) (1)

 0 cells /7.5 ml

No new: persistence from CTC3 12

  1. CTC 1: Baseline; CTC 2: After neoadjuvant androgen deprivation therapy and before radiotherapy; CTC 3: After radiotherapy; CTC 4: 6-12 months after radiotherapy in patients with new positivity at CTC 2 or CTC 3